Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (51-60 of 391) with videos related to

Pageof 40
Sort By:
The New England Journal of Medicine|August 24, 2022
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. ReplyLuca Richeldi, Susanne Stowasser, Toby M Maher
Advances in Therapy|April 13, 2018
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UKHelen Strongman, Imran Kausar, Toby M Maher
The Lancet. Respiratory Medicine|September 19, 2015
New guideline on treatment of idiopathic pulmonary fibrosisPaolo Spagnolo, Francesco Bonella, Toby M Maher
European Respiratory Review : an Official Journal of the European Respiratory Society|February 22, 2023
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosisMartin Kolb, Bruno Crestani, Toby M Maher
Current Opinion in Pulmonary Medicine|July 2, 2015
Personalized medicine in idiopathic pulmonary fibrosis: facts and promisesPaolo Spagnolo, Argyris Tzouvelekis, Toby M Maher
The New England Journal of Medicine|October 17, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. ReplyOliver Distler, Martina Gahlemann, Toby M Maher
Lancet (London, England)|August 14, 2022
Interstitial lung diseasesMarlies Wijsenbeek, Atsushi Suzuki, Toby M Maher
JAMA|September 12, 2023
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis-ReplyToby M Maher, Paul Ford, Marlies S Wijsenbeek
Journal of Managed Care & Specialty Pharmacy|March 14, 2017
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial HypertensionToby M Maher, Fred Dejonckheere, Steven D Nathan
The New England Journal of Medicine|October 1, 2025
Nerandomilast in Patients with Pulmonary Fibrosis. ReplyToby M Maher, Luca Richeldi, Donald F Zoz
Pageof 40

Showing results (51-60 of 391) with videos related to

Sort By:
Pageof 40
The New England Journal of Medicine|August 24, 2022
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. ReplyLuca Richeldi, Susanne Stowasser, Toby M Maher
Advances in Therapy|April 13, 2018
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UKHelen Strongman, Imran Kausar, Toby M Maher
The Lancet. Respiratory Medicine|September 19, 2015
New guideline on treatment of idiopathic pulmonary fibrosisPaolo Spagnolo, Francesco Bonella, Toby M Maher
European Respiratory Review : an Official Journal of the European Respiratory Society|February 22, 2023
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosisMartin Kolb, Bruno Crestani, Toby M Maher
Current Opinion in Pulmonary Medicine|July 2, 2015
Personalized medicine in idiopathic pulmonary fibrosis: facts and promisesPaolo Spagnolo, Argyris Tzouvelekis, Toby M Maher
The New England Journal of Medicine|October 17, 2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. ReplyOliver Distler, Martina Gahlemann, Toby M Maher
Lancet (London, England)|August 14, 2022
Interstitial lung diseasesMarlies Wijsenbeek, Atsushi Suzuki, Toby M Maher
JAMA|September 12, 2023
Ziritaxestat and Lung Function in Idiopathic Pulmonary Fibrosis-ReplyToby M Maher, Paul Ford, Marlies S Wijsenbeek
Journal of Managed Care & Specialty Pharmacy|March 14, 2017
Survival in Idiopathic Pulmonary Fibrosis: Perspectives from Pulmonary Arterial HypertensionToby M Maher, Fred Dejonckheere, Steven D Nathan
The New England Journal of Medicine|October 1, 2025
Nerandomilast in Patients with Pulmonary Fibrosis. ReplyToby M Maher, Luca Richeldi, Donald F Zoz
Pageof 40